Search

Displaying results 5371 - 5380 of 10000 in total
  1. Drug

    Guanoxan

    go.drugbank.com/drugs/DB13211
    Approved

    Guanoxan is an antihypertensive agent similar in its mechanism of action to guanethidine; may cause liver damage. … Guanoxan was approved in the UK but was withdrawn from the market due to hepatotoxicity.

  2. Drug

    Oftasceine

    go.drugbank.com/drugs/DB11184
    Approved

    Oftasceine is also referred to as Fluorexon. It is used in ophthalmic solutions as a staining agent when fitting soft and hard lenses. It is a fluorescent dye or luminescent agent.

  3. Drug

    SAR-260301

    go.drugbank.com/drugs/DB33608
    Investigational

    Categories: Class Ia Phosphatidylinositol 3-Kinase, antagonists & inhibitors
  4. Drug

    Becatecarin

    go.drugbank.com/drugs/DB06362
    Investigational

    Becatecarin is a derivative of [rebeccamycin].

  5. Drug

    Potassium carbonate

    go.drugbank.com/drugs/DB13977
    Approved

    Potassium carbonate (K2CO3) is a white salt, soluble in water (insoluble in ethanol) which forms a strongly alkaline solution. … It can be made as the product of potassium hydroxide's absorbent reaction with carbon dioxide. It presents a large capacity to absorb moisture.

  6. Drug

    Asvasiran

    go.drugbank.com/drugs/DB05638
    Investigational

    Asvasiran is an siRNA that targets the respiratory syncytial virus (RSV) N gene and inhibits viral replication. It has the potential to treat or prevent RSV infection.

  7. Drug

    Descartes-30

    go.drugbank.com/drugs/DB16361
    Investigational

    Descartes-30 is an RNA-engineered off-the-shelf allogeneic mesenchymal stem cell (MSC) product developed by Cartesian Therapeutics. … [L27531] The RNA-engineering is performed with Cartesian Therapeutics’ proprietary RNA Armory which is a platform that activates and provides cells with mRNA-based therapeutics.

  8. Drug

    MBX-2044

    go.drugbank.com/drugs/DB05598
    Investigational

    MBX-2044 was under investigation in clinical trial NCT00422487 (Safety and Tolerability Study of MBX-2044 in Patients With Type 2 Diabetes).

  9. Drug

    R112

    go.drugbank.com/drugs/DB06252
    Experimental

    R112 is an investigational compound developed to treat Allergic Rhinitis. It's mechanism of action is to inhibit SYK kinase.

  10. Drug

    IRX-2

    go.drugbank.com/drugs/DB05643
    Investigational

    It is being investigated to promote or enhance an anti-cancer immune response.